ZYME vs. ARCT

Last updated Jun 3, 2026

ZYME (Zymeworks Inc.) and ARCT (Arcturus Therapeutics Holdings Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ZYME returned -5.09%/yr vs -24.26%/yr for ARCT. At a 0.34 correlation, their price movements are largely independent.

Performance

ZYME vs. ARCT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zymeworks Inc. (ZYME) and Arcturus Therapeutics Holdings Inc. (ARCT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ZYME achieves a -8.43% return, which is significantly lower than ARCT's 24.80% return.

ZYME

• 1D: -1.75%
• 1M: -9.39%
• YTD: -8.43%
• 6M: -3.94%
• 1Y: 107.13%
• 3Y*: 40.62%
• 5Y*: -5.09%
• 10Y*: —

ARCT

• 1D: -1.54%
• 1M: -11.36%
• YTD: 24.80%
• 6M: 22.40%
• 1Y: -40.28%
• 3Y*: -34.22%
• 5Y*: -24.26%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ZYME vs. ARCT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ZYME Zymeworks Inc.	-8.43%	79.85%	40.90%	32.19%	-52.04%	-65.32%	29.80%
ARCT Arcturus Therapeutics Holdings Inc.	24.80%	-63.88%	-46.18%	85.91%	-54.17%	-14.68%	155.18%

Correlation

The correlation between ZYME and ARCT is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.34
Correlation (5Y) Calculated over the trailing 5-year period	0.36
Correlation (All Time) Calculated using the full available price history since Apr 17, 2020	0.34

Fundamentals

Market Cap ZYME : $1.80B ARCT : $217.42M
EPS ZYME : -$583.41 ARCT : -$1.81
PS Ratio ZYME : 23.17 ARCT : 4.50
PB Ratio ZYME : 0.01 ARCT : 1.14
Total Revenue (TTM) ZYME : $78.86M ARCT : $46.80M
Gross Profit (TTM) ZYME : $77.16M ARCT : $40.72M
EBITDA (TTM) ZYME : -$47.18B ARCT : -$84.61M

Return for Risk

ZYME vs. ARCT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZYME

ZYME Risk / Return Rank: 88
ZYME Sharpe Ratio Rank: 87
ZYME Sortino Ratio Rank: 87
ZYME Omega Ratio Rank: 85
ZYME Calmar Ratio Rank: 92
ZYME Martin Ratio Rank: 90

ARCT

ARCT Risk / Return Rank: 25
ARCT Sharpe Ratio Rank: 22
ARCT Sortino Ratio Rank: 28
ARCT Omega Ratio Rank: 28
ARCT Calmar Ratio Rank: 22
ARCT Martin Ratio Rank: 26

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ZYME vs. ARCT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zymeworks Inc. (ZYME) and Arcturus Therapeutics Holdings Inc. (ARCT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ZYME	ARCT	Difference
Sharpe ratio Return per unit of total volatility	2.03	-0.44	+2.47
Sortino ratio Return per unit of downside risk	2.99	-0.05	+3.04
Omega ratio Gain probability vs. loss probability	1.36	0.99	+0.37
Calmar ratio Return relative to maximum drawdown	5.47	-0.52	+5.99
Martin ratio Return relative to average drawdown	12.23	-0.74	+12.97
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ZYME vs. ARCT - Sharpe Ratio Comparison

The current ZYME Sharpe Ratio is 2.03, which is higher than the ARCT Sharpe Ratio of -0.44. The chart below compares the historical Sharpe Ratios of ZYME and ARCT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ZYME	ARCT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.03	-0.44	+2.47
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.08	-0.27	+0.18
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	-0.12	+0.23

Drawdowns

ZYME vs. ARCT - Drawdown Comparison

The maximum ZYME drawdown since its inception was -91.81%, roughly equal to the maximum ARCT drawdown of -95.23%. Use the drawdown chart below to compare losses from any high point for ZYME and ARCT.

Drawdown Indicators

	ZYME	ARCT	Difference
Max Drawdown Largest peak-to-trough decline	-91.81%	-95.23%	+3.42%
Max Drawdown (1Y) Largest decline over 1 year	-20.28%	-74.53%	+54.25%
Max Drawdown (3Y) Largest decline over 3 years	-45.75%	-86.71%	+40.96%
Max Drawdown (5Y) Largest decline over 5 years	-87.84%	-89.87%	+2.03%
Current Drawdown Current decline from peak	-57.56%	-93.81%	+36.25%
Average Drawdown Average peak-to-trough decline	-52.42%	-72.96%	+20.54%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.07%	52.60%	-43.53%

Volatility

ZYME vs. ARCT - Volatility Comparison

The current volatility for Zymeworks Inc. (ZYME) is 14.09%, while Arcturus Therapeutics Holdings Inc. (ARCT) has a volatility of 18.67%. This indicates that ZYME experiences smaller price fluctuations and is considered to be less risky than ARCT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ZYME	ARCT	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.09%	18.67%	-4.58%
Volatility (6M) Calculated over the trailing 6-month period	29.62%	40.39%	-10.77%
Volatility (1Y) Calculated over the trailing 1-year period	53.13%	92.42%	-39.29%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	61.94%	91.77%	-29.83%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	61.57%	102.26%	-40.69%

Dividends

ZYME vs. ARCT - Dividend Comparison

Neither ZYME nor ARCT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ZYME and ARCT in my portfolio?

ZYME and ARCT have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ZYME or ARCT?

ARCT has higher volatility (18.67%) compared to ZYME (14.09%). In terms of maximum drawdown, ZYME dropped -91.81% vs ARCT's -95.23%.

Which has better risk-adjusted returns?

ZYME currently has the higher Sharpe Ratio (2.03 vs -0.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.